Chargement de la fiche…
Chargement de la fiche…
Hospitalo-universitaire
Photo : Mariette, Public domain, Wikimedia Commons
Dans les médias
Vous êtes Pr Christophe Richez ? Présentation, expertises, actes, site du cabinet : faites de cette fiche la page de votre cabinet.
Configurer votre fiche gratuitement →Pr Christophe Richez est rhumatologue à Bordeaux (33076). Il consulte à GROUPE HOSPITALIER PELLEGRIN - CHU, Place AMELIE RABA LEON, 33076 Bordeaux.
Consulter
GROUPE HOSPITALIER PELLEGRIN - CHU
Place AMELIE RABA LEON, 33076 Bordeaux
Pr Christophe Richez, c'est vous ?
Faites de cette fiche la page de votre cabinet.
Hospitalier
Pour aller plus loin
Remboursement
Pratique
Thèmes de publication
Domaines déduits des publications référencées sur PubMed.
Faits issus de registres publics et des déclarations du praticien — aucun classement.
DES Rhumatologie · Rhumatologie (SM) — Diplôme d'études spécialisées
DE Docteur en médecine — Capacité / certificat d'études spéciales
Les plus citées
2025The Lancet. Rheumatology55 citations
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?
2025The Lancet. Rheumatology25 citations
Baricitinib in early polymyalgia rheumatica (BACHELOR): a randomised, double-blind, placebo-controlled, parallel-group trial
2024Joint bone spine20 citations
2024 update of the recommendations of the French Society of Rheumatology for the diagnosis and management of patients with rheumatoid arthritis
Contenus publics où le nom du praticien apparaît (YouTube, Google Actualités).
En bref
Pr Christophe Richez consulte à GROUPE HOSPITALIER PELLEGRIN - CHU, Place AMELIE RABA LEON, 33076 Bordeaux. Adresses issues de l'Annuaire Santé (ANS).
Par téléphone au 05 56 79 56 79 (numéro publié à l'Annuaire Santé). Un lien de recherche Doctolib est proposé sur cette page : si le praticien y est inscrit, son profil figure normalement parmi les résultats.
Identité, diplômes et lieux d'exercice : Annuaire Santé (ANS, licence ouverte). Conventionnement et carte Vitale : Assurance Maladie. Publications : bases scientifiques publiques (PubMed, HAL, OpenAlex), affichées seulement si le nom du praticien figure parmi les auteurs. Le praticien peut corriger sa fiche ou en demander le retrait à tout moment ; en cas d'homonymie, signalez-le.
Autour du cabinet
Vous pouvez aussi demander le retrait de la fiche.
Aperçu de votre présentation
Rhumatologue à Bordeaux, j'accompagne…
Exemple : vous choisissez vos propres domaines.
Innovative therapies in rheumatoid arthritis: CAR T cells and bispecific antibodies
2026EBioMedicinePubMed
Exome sequencing enables molecular diagnosis in 10% of early-onset or familial systemic lupus erythematosus cases
2025Expert review of clinical pharmacologyPubMed
Pharmacology considerations for managing pregnancy in women with systemic lupus erythematosus
2025The Lancet. RheumatologyPubMed
ERN ReCONNET-SLICC-SLEuro expert consensus on the therapeutic management of rare systemic lupus erythematosus manifestations
2025BJOG : an international journal of obstetrics and gynaecologyPubMed
Safety of Fertility Treatments in Women With Systemic Lupus Erythematosus: Data From a Prospective Population-Based Study
2025Rheumatology (Oxford, England)PubMed
Hydroxychloroquine levels in pregnancy and materno-fetal outcomes in systemic lupus erythematosus patients
2024Journal of clinical medicinePubMed
No Effect of Low-Dose Glucocorticoid Maintenance Therapy on Damage in SLE Patients in Prolonged Remission: A Propensity Score Analysis of the Longitudinal Lupus-Cruces-Bordeaux Inception Cohort
2024La Revue de medecine internePubMed
French protocol for the diagnosis and management of systemic lupus erythematosus
2024Arthritis care & researchPubMed
Methylprednisolone Pulses and Prolonged Remission in Systemic Lupus Erythematosus: A Propensity Score Analysis of the Longitudinal Lupus-Cruces-Bordeaux Inception Cohort
2024Expert review of clinical immunologyPubMed
Anifrolumab: first biologic approved in the EU not restricted to patients with a high degree of disease activity for the treatment of moderate to severe systemic lupus erythematosus
2026Joint bone spinePubMed
Answer to Elbaz et al
2026BMC women's healthPubMed
Cervical cancer screening practices among patients with autoimmune and inflammatory rheumatic diseases: a descriptive cross-sectional observational study
2026Joint bone spinePubMed
Skin cancer risk in patients with non-dermatologic immune-mediated inflammatory diseases
2025The Lancet. RheumatologyPubMed
CAR T-cell therapy in autoimmune diseases: where are we and where are we going?
2025Lupus science & medicinePubMed
Anti-CD20 alone as maintenance immunosuppressive therapy in severe lupus nephritis: a promising experience that needs to be evaluated
2025RMD openPubMed
Efficacy of valaciclovir in preventing herpes zoster in patients receiving anifrolumab
2025Joint bone spinePubMed
Resolution of immune checkpoint inhibitors-induced inflammatory arthritis while maintaining active treatment with checkpoint inhibitors and after its discontinuation: An observational study
2024Nature communicationsPubMed
Inflammasome-targeted therapy might prevent adverse perinatal outcomes of recurrent chronic intervillositis of unknown etiology
2025Drug safetyPubMed
Correction: Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database
2025Drug safetyPubMed
Correction: Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database
2025Drug safetyPubMed
Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database
2025ACR open rheumatologyPubMed
Analysis of the Impact of Tofacitinib Treatment on Weight and Body Mass Index in Patients With Rheumatoid Arthritis
2025The Lancet. RheumatologyPubMed
Baricitinib in early polymyalgia rheumatica (BACHELOR): a randomised, double-blind, placebo-controlled, parallel-group trial
2024Rheumatology (Oxford, England)PubMed
Evolution of monoclonal gammopathy of undetermined significance in patients treated with JAK inhibitors for rheumatic diseases: data from the MAJIK-SFR registry
2026RMD openPubMed
Impact of postpartum on patients with rheumatoid arthritis and spondyloarthritis: an ancillary analysis of the GR2 prospective cohort
2026Annals of the rheumatic diseasesPubMed
Evaluation of pregnancy outcomes in patients with spondyloarthritis compared to the general population: results from a French national prospective and matched study
2025BMC rheumatologyPubMed
Disease activity during pregnancy in patients with rheumatoid arthritis or spondyloarthritis: results from the multicentre prospective GR2 study
2024RMD openPubMed
NSAID exposure delays time-to-pregnancy in patients with spondyloarthritis: an analysis of the GR2 prospective cohort
2024Clinical and experimental rheumatologyPubMed
Comparison of SARS-COV-2 humoral response between rheumatoid arthritis, psoriatic arthritis and spondyloarthritis patients and controls in two unvaccinated cohorts
2026BMC rheumatologyPubMed
Prevalence of effective contraceptive use among patients with rheumatic diseases: a descriptive study
2024Rheumatology (Oxford, England)PubMed
Prophylaxis with tixagevimab/cilgavimab is associated with lower COVID-19 incidence and severity in patients with autoimmune diseases
2024The Journal of infectionPubMed
Diagnosis and treatment of Tropheryma whipplei infection in patients with inflammatory rheumatic disease: Data from the French Tw-IRD registry
2024Arthritis care & researchPubMed
Impact of Risk Factors on COVID-19 Outcomes in Unvaccinated People With Rheumatic Diseases: A Comparative Analysis of Pandemic Epochs Using the COVID-19 Global Rheumatology Alliance Registry
2025La Revue de medecine internePubMed
Use of immunosuppressants and biologics in giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA)
2025La Revue de medecine internePubMed
French protocol for the diagnosis and management of giant cell arteritis
2024Seminars in arthritis and rheumatismPubMed
Giant cell arteritis associated with scalp, tongue or lip necrosis: A French multicenter case control study
2025Arthritis & rheumatology (Hoboken, N.J.)PubMed
Maintenance of Remission After Tocilizumab Withdrawal in Patients With Glucocorticoid-Dependent Polymyalgia Rheumatica
2025The Lancet. RheumatologyPubMed
Baricitinib in early polymyalgia rheumatica (BACHELOR): a randomised, double-blind, placebo-controlled, parallel-group trial
2024RMD openPubMed
Concordance and agreement between different activity scores in polymyalgia rheumatica
2025Arthritis & rheumatology (Hoboken, N.J.)PubMed
Maintenance of Remission After Tocilizumab Withdrawal in Patients With Glucocorticoid-Dependent Polymyalgia Rheumatica
2025BMJ openPubMed
Abatacept versus tocilizumab for the treatment of rheumatoid arthritis in TNF inhibitor inadequate responders: study protocol of the SUNSTAR randomised controlled open-label superiority trial
2025The Lancet. RheumatologyPubMed
Effect of a 1-month methotrexate delay on pneumococcal vaccine immunogenicity and disease control in patients with early rheumatoid arthritis (VACIMRA): an open-label randomised trial
2025Rheumatology (Oxford, England)PubMed
Hydroxychloroquine levels in pregnancy and materno-fetal outcomes in systemic lupus erythematosus patients
2026Nature communicationsPubMed
Soluble CD95L triggers Caspase-10-driven reactive oxygen species production in neutrophils and aggravates anti-neutrophil cytoplasmic antibody-vasculitis
2025La Revue de medecine internePubMed
Use of immunosuppressants and biologics in giant cell arteritis: Recommendations of the French Study Group for Large Vessel Vasculitis (GEFA)
2026 · Article
Answer to Elbaz et al.
2026 · Article
[Translation into French and republication of: "French recommendations for the use of Imaging in Giant Cell Arteritis"].
2026 · Article
Rapid efficacy of anifrolumab in refractory cutaneous dermatomyositis
2026 · Article
Evaluation of pregnancy outcomes in patients with rheumatoid arthritis compared with the general population: results from a French national prospective and matched study
2026 · Article
Soluble CD95L triggers Caspase-10-driven reactive oxygen species production in neutrophils and aggravates anti-neutrophil cytoplasmic antibody-vasculitis
2026 · Article
Impact of postpartum on patients with rheumatoid arthritis and spondyloarthritis: an ancillary analysis of the GR2 prospective cohort
2026 · Article
Cervical cancer screening practices among patients with autoimmune and inflammatory rheumatic diseases: a descriptive cross-sectional observational study
2026 · Article
Exome sequencing enables molecular diagnosis in 10% of early-onset or familial systemic lupus erythematosus cases
Publications affichées uniquement lorsque le nom du praticien figure parmi les auteurs. Une erreur d'homonymie ? Signalez-la depuis le lien en bas de page.
2020 · doctorant : Marc Scherlinger
Les sélectines inhibent la fonction des lymphocytes T régulateurs et contribuent à la pathogénie du lupus érythémateux systémique
2014 · doctorant : Liliane Khoryati
Propriétés immuno-modulatrices des IgE dans le lupus érythémateux systémique : impact sur la sécrétion d’interféron de type I par les cellules dendritiques plasmacytoïdes